Skip to content
stoqly

MiniMed Group, Inc.

MMED Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2024–FY2026

Revenue Total sales reported in the income statement.
$3.1B
14.3% vs prior year
Operating margin Operating income as a share of revenue.
−6.1%
0.7 pts
Net income Profit after all expenses, interest and tax.
−$333M
Free cash flow Cash from operations minus capital spending.
−$420M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.30 EPS (TTM)

What MiniMed Group, Inc. does

No business description yet.

Legal name
MiniMed Group, Inc.
Fiscal year ends
April 24, 2026
Latest annual report
10-K · Jun 29, 2026
Accession · CIK
0001628280-26-045915
0002062583

Revenue and margins

MiniMed Group, Inc. had $3.1B of revenue in fiscal 2026, up 14.3% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$420M in fiscal 2026, −13.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

MiniMed Group, Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 1.5%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably MiniMed Group, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY24FY25FY26
Cash and short-term investments $54.0M$11.0M$298M
Current ratio —1.3x1.9x
Quick ratio —0.9x1.4x
Total assets —$4.2B$4.6B
Total liabilities —$871M$1.0B
Shareholders' equity $3.4B$3.3B$3.6B
Net debt (− = net cash) ———

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY24FY25FY26
Net income is positive ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✕
Return on assets rose — — ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets — — —
Current ratio rose — — ✓
Share count didn't rise — ✓ ✕
Gross margin rose — ✕ ✕
Revenue rose relative to assets — — ✓
F-score — / 3— / 53 / 8
Accruals ratio —−8.4%−3.1%
Altman Z'' —4.144.28

3 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY24FY25FY26
Income statement
Revenue $2.5B $2.7B $3.1B
Gross profit $1.4B $1.5B $1.7B
Research and development $437M $436M $448M
Operating income −$69.0M −$146M −$190M
Pretax income −$70.0M −$147M −$189M
Income tax $38.0M $52.0M $128M
Net income −$112M −$213M −$333M
Diluted EPS −$0.44 −$0.84 −$1.30
Diluted shares 0.25B 0.25B 0.26B
Cash flow
Cash from operations $41.0M $140M −$197M
Capital expenditure $148M $193M $223M
Free cash flow −$107M −$53.0M −$420M
Depreciation and amortization $129M $143M $156M
Stock-based compensation $38.0M $41.0M $46.0M
Balance sheet
Cash and short-term investments $54.0M $11.0M $298M
Current assets — $939M $1.3B
Current liabilities — $710M $702M
Inventory — $311M $341M
Property and equipment, net — $706M $711M
Goodwill — $2.3B $2.3B
Intangible assets — $132M $107M
Total assets — $4.2B $4.6B
Total liabilities — $871M $1.0B
Preferred stock — $0.0M $0.0M
Shareholders' equity $3.4B $3.3B $3.6B
Margins
Gross margin 58.2% 56.3% 54.2%
Operating margin −2.8% −5.4% −6.1%
EBITDA margin 2.4% −0.1% −1.1%
Net margin −4.5% −7.8% −10.7%
FCF margin −4.3% −2.0% −13.5%
Returns
Return on capital employed — −4.2% −4.8%
Return on equity −3.2% −6.3% −9.6%
Return on assets — −5.1% −7.5%
Return on tangible equity −3.2% −22.6% −26.7%
Growth
Revenue growth — 10.0% 14.3%
Share count change — 0.0% 1.5%
Financial health
Current ratio — 1.3x 1.9x
Quick ratio — 0.9x 1.4x
Capital allocation
Capex / revenue 6.0% 7.1% 7.2%
Stock comp / revenue 1.5% 1.5% 1.5%
Quality scores
Piotroski F-score — — 3.0
Altman Z'' — 4.1 4.3
Accruals ratio — −8.4% −3.1%

Source: SEC EDGAR XBRL filings (CIK 0002062583). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open